Please login to the form below

Not currently logged in
Email:
Password:

ImmTAC

This page shows the latest ImmTAC news and features for those working in and with pharma, biotech and healthcare.

Roche builds on Immunocore ImmTAC deal

Roche builds on Immunocore ImmTAC deal

The outcome of that initial partnership was to develop a number of novel cancer candidates by using Immunocore’s TCR technology known as ImmTAC (Immune Mobilising Monoclonal TCRs Against Cancer) molecules.

Latest news

  • Lilly and Immunocore ink immunotherapy R&D deal Lilly and Immunocore ink immunotherapy R&D deal

    IMCgp100 is Immunocore's most advanced Immune mobilising mTCR Against Cancer molecules (ImmTAC), which are a new class of bi-specific biologic drugs based on T-cell receptors (TCRs) with ... novel T-cell-based cancer therapies built on Immunocore's

  • MedImmune and Immunocore to join on melanoma trials MedImmune and Immunocore to join on melanoma trials

    The firms already have a pre-existing research collaboration and licensing agreement to develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptior Against Caner(immTAC) technology.

  • Lilly steps up cancer immunotherapy research Lilly steps up cancer immunotherapy research

    Other companies to agree deals with Immunocore include GlaxoSmithKline, Roche and AstraZeneca, all of which involve Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC). ... We believe Immunocore's ImmTAC platform has the

  • AZ agrees cancer alliance with Immunocore

    The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to

  • GSK signs $500m-plus technology deal with Immunocore GSK signs $500m-plus technology deal with Immunocore

    Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells. ... Immunocore specialises in the development bi-specific biological drugs known as ImmTACs (see image) that combine with T cell receptors, which recognise

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    30. Immunocore/ Eli Lilly. Co-discovery /co-development, options (cost/profit share). ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery)    . 25+. Noven Therapeutics/ ANI Pharmaceuticals. Acquisition of NDA †. Lithobid

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    337.5. Immunocore/AZ Medimmune. Collaboration and licence. Immune mobilising monoclonal T-Cell receptor against cancer (ImmTAC) therapies.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Research collaboration and licence. ImmTacs discovery platform against multiple targets. 510. ... Abbreviations. ImmTacs = Immune mobilising mTCR against cancer. CLL = chronic lymphocytic leukaemia.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    490. Immunocore / Genentech. Research collaboration and licence. Discovery and development of multiple targets using Immunocore's ImmTAC technology (platform)  . 320+. Medicines360 / Actavis. Licence. US commercial rights to LNG20 Intrauterine

  • Pharma deals during June 2013 Pharma deals during June 2013

    Immunocore for the discovery and development of multiple novel cancer targets using Immunocore's ImmTAC platform.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Immunocore names CEO Immunocore names CEO

    His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC pipeline.".

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...